Approaching Cell Therapy Supply Chain from a “Big Pharma” Perspective to Enable Industrial-Scale Delivery of Autologous and Allogeneic Treatments

Time: 9:00 am
day: Day One


  • Identifying the differentiating components of cell and gene therapy supply chains, and how to approach industrial scale readiness
  • Examining synergies with existing infrastructure from other pharmaceutical pipelines to ease integration
  • Discussing the ‘layers’ of a cell therapy supply chain, and the implications of ‘make to order’ and patient centric settings
  • Drawing parallels across clinical and commercial scale supply chains and questioning the need to develop them separately